Login Register Cart 0
Current Neuropharmacology

Current Neuropharmacology

Editor-in-Chief

ISSN (Print): 1570-159X
ISSN (Online): 1875-6190

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

Emerging Therapeutic Targets for Spontaneous Intracerebral Hemorrhage

Author(s): Alessandro Pezzini*

Volume 23, Issue 14, 2025

Published on: 11 July, 2025

Page: [1979 - 1984] Pages: 6

DOI: 10.2174/011570159X390388250708063345

Become a Editorial Board Member
Become a Reviewer
Become a Editor
Become a Section Editor
« Previous Next »
[1]
Seiffge, D.J.; Fandler-Höfler, S.; Du, Y.; Goeldlin, M.B.; Jolink, W.M.T.; Klijn, C.J.M.; Werring, D.J. Intracerebral haemorrhage — mechanisms, diagnosis and prospects for treatment and prevention. Nat. Rev. Neurol., 2024, 20(12), 708-723.
[http://dx.doi.org/10.1038/s41582-024-01035-w] [PMID: 39548285]
[2]
Morris, N.A.; Simard, J.M.; Chaturvedi, S. Surgical management for primary intracerebral hemorrhage. Neurology, 2024, 103(4), e209714.
[http://dx.doi.org/10.1212/WNL.0000000000209714] [PMID: 39074339]
[3]
Chang, C.F.; Goods, B.A.; Askenase, M.H.; Hammond, M.D.; Renfroe, S.C.; Steinschneider, A.F.; Landreneau, M.J.; Ai, Y.; Beatty, H.E.; da Costa, L.H.A.; Mack, M.; Sheth, K.N.; Greer, D.M.; Huttner, A.; Coman, D.; Hyder, F.; Ghosh, S.; Rothlin, C.V.; Love, J.C.; Sansing, L.H. Erythrocyte efferocytosis modulates macrophages towards recovery after intracerebral hemorrhage. J. Clin. Invest., 2017, 128(2), 607-624.
[http://dx.doi.org/10.1172/JCI95612] [PMID: 29251628]
[4]
Röszer, T. Transcriptional control of apoptotic cell clearance by macrophage nuclear receptors. Apoptosis, 2017, 22(2), 284-294.
[http://dx.doi.org/10.1007/s10495-016-1310-x] [PMID: 27787652]
[5]
Wang, G.; Li, T.; Duan, S.; Dong, L.; Sun, X.; Xue, F. PPAR-Ƴ promotes hematoma clearance through haptoglobin-hemoglobin-CD163 in a rat model of intracerebral hemorrhage. Behav. Neurol., 2018, 2018, 1-7.
[http://dx.doi.org/10.1155/2018/7646104]
[6]
Gonzales, N.R.; Shah, J.; Sangha, N.; Sosa, L.; Martinez, R.; Shen, L.; Kasam, M.; Morales, M.M.; Hossain, M.M.; Barreto, A.D.; Savitz, S.I.; Lopez, G.; Misra, V.; Wu, T.C.; Khoury, R.E.; Sarraj, A.; Sahota, P.; Hicks, W.; Acosta, I.; Sline, M.R.; Rahbar, M.H.; Zhao, X.; Aronowski, J.; Grotta, J.C. Design of a prospective, dose-escalation study evaluating the safety of pioglitazone for hematoma resolution in intracerebral hemorrhage (SHRINC). Int. J. Stroke, 2013, 8(5), 388-396.
[http://dx.doi.org/10.1111/j.1747-4949.2011.00761.x] [PMID: 22340518]
[7]
Wan, J.; Ren, H.; Wang, J. Iron toxicity, lipid peroxidation and ferroptosis after intracerebral haemorrhage. Stroke Vasc. Neurol., 2019, 4(2), 93-95.
[http://dx.doi.org/10.1136/svn-2018-000205] [PMID: 31338218]
[8]
Selim, M.; Foster, L.D.; Moy, C.S.; Xi, G.; Hill, M.D.; Morgenstern, L.B.; Greenberg, S.M.; James, M.L.; Singh, V.; Clark, W.M.; Norton, C.; Palesch, Y.Y.; Yeatts, S.D.; Dolan, M.; Yeh, E.; Sheth, K.; Kunze, K.; Muehlschlegel, S.; Nieto, I.; Claassen, J.; Falo, C.; Huang, D.; Beckwith, A.; Messe, S.; Yates, M.; O’Phelan, K.; Escobar, A.; Becker, K.; Tanzi, P.; Gonzales, N.; Tremont, C.; Venkatasubramanian, C.; Thiessen, R.; Save, S.; Verrault, S.; Collard, K.; DeGeorgia, M.; Cwiklinski, V.; Thompson, B.; Wasilewski, L.; Andrews, C.; Burfeind, R.; Torbey, M.; Hamed, M.; Butcher, K.; Sivakumar, L.; Varelas, N.; Mays-Wilson, K.; Leira, E.; Olalde, H.; Silliman, S.; Calhoun, R.; Dangayach, N.; Renvill, R.; Malhotra, R.; Kordesch, K.; Lord, A.; Calahan, T.; Geocadin, R.; Parish, M.; Frey, J.; Harrigan, M.; Leifer, D.; Mathias, R.; Schneck, M.; Bernier, T.; Gonzales-Arias, S.; Elysee, J.; Lopez, G.; Volgi, J.; Brown, R.; Jasak, S.; Phillips, S.; Jarrett, J.; Gomes, J.; McBride, M.; Aldrich, F.; Aldrich, C.; Kornbluth, J.; Bettle, M.; Goldstein, J.; Tirrell, G.; Shaw, Q.; Jonczak, K. Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): A multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurol., 2019, 18(5), 428-438.
[http://dx.doi.org/10.1016/S1474-4422(19)30069-9] [PMID: 30898550]
[9]
Foster, L.; Robinson, L.; Yeatts, S.D.; Conwit, R.A.; Shehadah, A.; Lioutas, V.; Selim, M. i-DEF Investigators. Effect of deferoxamine on trajectory of recovery after intracerebral hemorrhage: A post hoc analysis of the i-DEF Trial. Stroke, 2022, 53(7), 2204-2210.
[http://dx.doi.org/10.1161/STROKEAHA.121.037298] [PMID: 35306827]
[10]
Fouda, A.Y.; Newsome, A.S.; Spellicy, S.; Waller, J.L.; Zhi, W.; Hess, D.C.; Ergul, A.; Edwards, D.J.; Fagan, S.C.; Switzer, J.A. Minocycline in acute cerebral hemorrhage: An early phase randomized trial. Stroke, 2017, 48(10), 2885-2887.
[http://dx.doi.org/10.1161/STROKEAHA.117.018658] [PMID: 28887388]
[11]
Chang, J.J.; Kim-Tenser, M.; Emanuel, B.A.; Jones, G.M.; Chapple, K.; Alikhani, A.; Sanossian, N.; Mack, W.J.; Tsivgoulis, G.; Alexandrov, A.V.; Pourmotabbed, T. Minocycline and matrix metalloproteinase inhibition in acute intracerebral hemorrhage: A pilot study. Eur. J. Neurol., 2017, 24(11), 1384-1391.
[http://dx.doi.org/10.1111/ene.13403] [PMID: 28929560]
[12]
Voigt, S.; Koemans, E.A.; Rasing, I.; van Etten, E.S.; Terwindt, G.M.; Baas, F.; Kaushik, K.; van Es, A.C.G.M.; van Buchem, M.A.; van Osch, M.J.P.; van Walderveen, M.A.A.; Klijn, C.J.M.; Verbeek, M.M.; van der Weerd, L.; Wermer, M.J.H. Minocycline for sporadic and hereditary cerebral amyloid angiopathy (BATMAN): Study protocol for a placebo-controlled randomized double-blind trial. Trials, 2023, 24(1), 378.
[http://dx.doi.org/10.1186/s13063-023-07371-4] [PMID: 37277877]
[13]
Parry-Jones, A.R.; Stocking, K.; MacLeod, M.J.; Clarke, B.; Werring, D.J.; Muir, K.W.; Vail, A. Phase II randomised, placebo-controlled, clinical trial of interleukin-1 receptor antagonist in intracerebral haemorrhage: Blocking the cytokine IL-1 in ICH (BLOC-ICH). Eur. Stroke J., 2023, 8(3), 819-827.
[http://dx.doi.org/10.1177/23969873231185208] [PMID: 37452707]
[14]
Cliteur, M.P.; van der Kolk, A.G.; Hannink, G.; Hofmeijer, J.; Jolink, W.M.T.; Klijn, C.J.M.; Schreuder, F.H.B.M. Anakinra in cerebral haemorrhage to target secondary injury resulting from neuroinflammation (ACTION): Study protocol of a phase II randomised clinical trial. Eur. Stroke J., 2024, 9(1), 265-273.
[http://dx.doi.org/10.1177/23969873231200686] [PMID: 37713268]
[15]
Fu, Y.; Hao, J.; Zhang, N.; Ren, L.; Sun, N.; Li, Y.J.; Yan, Y.; Huang, D.; Yu, C.; Shi, F.D. Fingolimod for the treatment of intracerebral hemorrhage: A 2-arm proof-of-concept study. JAMA Neurol., 2014, 71(9), 1092-1101.
[http://dx.doi.org/10.1001/jamaneurol.2014.1065] [PMID: 25003359]
[16]
A phase II, patient- and investigator-blinded, randomized, placebo-controlled study to evaluate efficacy, safety and tolerability of BAF312 (siponimod) in patients with stroke due to intracerebral hemorrhage (ICH). 2021. Available from: https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17824
[17]
Jiang, B.; Li, L.; Chen, Q.; Tao, Y.; Yang, L.; Zhang, B.; Zhang, J.H.; Feng, H.; Chen, Z.; Tang, J.; Zhu, G. Role of glibenclamide in brain injury after intracerebral hemorrhage. Transl. Stroke Res., 2017, 8(2), 183-193.
[http://dx.doi.org/10.1007/s12975-016-0506-2] [PMID: 27807801]
[18]
Zhao, J.; Song, C.; Li, D.; Yang, X.; Yu, L.; Wang, K.; Wu, J.; Wang, X.; Li, D.; Zhang, B.; Li, B.; Guo, J.; Feng, W.; Fu, F.; Gu, X.; Qian, J.; Li, J.; Yuan, X.; Liu, Q.; Chen, J.; Wang, X.; Liu, Y.; Wei, D.; Wang, L.; Shang, L.; Yang, F.; Jiang, W. Efficacy and safety of glibenclamide therapy after intracerebral haemorrhage (GATE-ICH): A multicentre, prospective, randomised, controlled, open-label, blinded-endpoint, phase 2 clinical trial. EClin. Med., 2022, 53, 101666.
[http://dx.doi.org/10.1016/j.eclinm.2022.101666] [PMID: 36177443]
[19]
Chu, K.; Jeong, S.W.; Jung, K.H.; Han, S.Y.; Lee, S.T.; Kim, M.; Roh, J.K. Celecoxib induces functional recovery after intracerebral hemorrhage with reduction of brain edema and perihematomal cell death. J. Cereb. Blood Flow Metab., 2004, 24(8), 926-933.
[http://dx.doi.org/10.1097/01.WCB.0000130866.25040.7D] [PMID: 15362723]
[20]
Lee, S.H.; Park, H.K.; Ryu, W.S.; Lee, J.S.; Bae, H.J.; Han, M.K.; Lee, Y.S.; Kwon, H.M.; Kim, C.K.; Park, E.S.; Chung, J.W.; Jung, K.H.; Roh, J.K. Effects of celecoxib on hematoma and edema volumes in primary intracerebral hemorrhage: A multicenter randomized controlled trial. Eur. J. Neurol., 2013, 20(8), 1161-1169.
[http://dx.doi.org/10.1111/ene.12140] [PMID: 23551657]
[21]
Marini, S.; Crawford, K.; Morotti, A.; Lee, M.J.; Pezzini, A.; Moomaw, C.J.; Flaherty, M.L.; Montaner, J.; Roquer, J.; Jimenez-Conde, J.; Giralt-Steinhauer, E.; Elosua, R.; Cuadrado-Godia, E.; Soriano-Tarraga, C.; Slowik, A.; Jagiella, J.M.; Pera, J.; Urbanik, A.; Pichler, A.; Hansen, B.M.; McCauley, J.L.; Tirschwell, D.L.; Selim, M.; Brown, D.L.; Silliman, S.L.; Worrall, B.B.; Meschia, J.F.; Kidwell, C.S.; Testai, F.D.; Kittner, S.J.; Schmidt, H.; Enzinger, C.; Deary, I.J.; Rannikmae, K.; Samarasekera, N.; Salman, R.A-S.; Sudlow, C.L.; Klijn, C.J.M.; van Nieuwenhuizen, K.M.; Fernandez-Cadenas, I.; Delgado, P.; Norrving, B.; Lindgren, A.; Goldstein, J.N.; Viswanathan, A.; Greenberg, S.M.; Falcone, G.J.; Biffi, A.; Langefeld, C.D.; Woo, D.; Rosand, J.; Anderson, C.D. Association of apolipoprotein E with intracerebral hemorrhage risk by race/ethnicity. JAMA Neurol., 2019, 76(4), 480-491.
[http://dx.doi.org/10.1001/jamaneurol.2018.4519] [PMID: 30726504]
[22]
Marchina, S.; Yeatts, S.D.; Foster, L.D.; Janis, S.; Shoamanesh, A.; Khatri, P.; Bernstein, K.; Perlmutter, A.; Stever, C.; Heistand, E.C.; Broderick, J.P.; Greenberg, S.M.; Leira, E.C.; Rosand, J.; Lioutas, V.A.; Salman, R.A.S.; Tirschwell, D.; Marti-Fabregas, J.; Selim, M. Rationale and design of the statin use in intracerebral hemorrhage patients (SATURN) trial. Cerebrovasc. Dis., 2025, 54(2), 270-277.
[http://dx.doi.org/10.1159/000538195] [PMID: 38493765]
[23]
Gao, D.; Chu, X.; Zhang, Y.; Yan, H.; Niu, L.; Jiang, X.; Bao, S.; Ji, X.; Wu, C. Statins for neuroprotection in spontaneous intracerebral haemorrhage (STATIC): Protocol for a multicentre, prospective and randomised controlled trial. BMJ Open, 2024, 14(6), e079879.
[http://dx.doi.org/10.1136/bmjopen-2023-079879] [PMID: 38908848]
[24]
Li, M.; Ren, H.; Sheth, K.N.; Shi, F.D.; Liu, Q. A TSPO ligand attenuates brain injury after intracerebral hemorrhage. FASEB J., 2017, 31(8), 3278-3287.
[http://dx.doi.org/10.1096/fj.201601377RR] [PMID: 28416580]
[25]
Zhang, T.; Xia, F.; Wan, Y.; Xi, G.; Ya, H.; Keep, R.F. Complement inhibition reduces early erythrolysis, attenuates brain injury, hydrocephalus, and iron accumulation after intraventricular hemorrhage in aged rats. Transl. Stroke Res., 2025, 16(3), 882-895.
[http://dx.doi.org/10.1007/s12975-024-01273-6] [PMID: 38943026]
[26]
Wang, Z.; Li, Y.; Wang, Z.; Liao, Y.; Ye, Q.; Tang, S.; Wei, T.; Xiao, P.; Huang, J.; Lu, W. Edaravone maintains AQP4 polarity via OS/MMP9/b-DG pathway in an experimental intracerebral hemorrhage mouse model. Mol. Neurobiol., 2024, 61(10), 7659-7660.
[http://dx.doi.org/10.1007/s12035-024-04275-5] [PMID: 38833129]
[27]
Shi, S.X.; Li, Y.J.; Shi, K.; Wood, K.; Ducruet, A.F.; Liu, Q. (Interleukin)-15 bridges astrocyte-microglia crosstalk and exacerbates brain injury following intracerebral hemorrhage. Stroke, 2020, 51(3), 967-974.
[http://dx.doi.org/10.1161/STROKEAHA.119.028638] [PMID: 32019481]
[28]
Gao, Y.; Ma, L.; Luo, C.; Wang, T.; Zhang, M.; Shen, X.; Meng, H.; Ji, M.; Wang, Z.; Chen, X.; Tao, L. IL-33 exerts neuroprotective effect in mice intracerebral hemorrhage model through suppressing inflammation/apoptotic/autophagic pathway. Mol. Neurobiol., 2017, 54(5), 3879-3892.
[http://dx.doi.org/10.1007/s12035-016-9947-6] [PMID: 27405469]
[29]
Zhao, X.; Ting, S.M.; Liu, C.H.; Sun, G.; Kruzel, M.; Roy-O’Reilly, M.; Aronowski, J. Neutrophil polarization by IL-27 as a therapeutic target for intracerebral hemorrhage. Nat. Commun., 2017, 8(1), 602.
[http://dx.doi.org/10.1038/s41467-017-00770-7] [PMID: 28928459]
[30]
Han, R.; Luo, J.; Shi, Y.; Yao, Y.; Hao, J. PD-L1 (programmed death ligand 1) protects against experimental intracerebral hemorrhage-induced brain injury. Stroke, 2017, 48(8), 2255-2262.
[http://dx.doi.org/10.1161/STROKEAHA.117.016705] [PMID: 28706113]

Rights & Permissions Print Cite
Article Metrics
Pdf icon 21
Html icon 2
Find your institution